The importance of early diagnosis of Alzheimer's disease (AD) is highlighted in a new series of documentaries that were presented under the name "Nature's Building Blocks” on 16 June, during the BIO International Convention.
Initiated by the ICBA (International Council of Biotechnology Associations), the series aims at exploring innovations and partnerships that are driving biotechnology industries forward, through the personal stories of the people behind the science and those whose lives and livelihoods depend on it. The ICBA has invited a number of biotechnology companies to participate in the series of documentaries, all of which are produced by BBC StoryWorks.
Fujirebio, the in vitro diagnostics company with a long history of AD diagnostic solutions and partnerships, was invited to participate in the series. It decided to do so with a video dedicated to AD testing. The video, released on 24 June 2021, follows 53-year-old Daniel Du Rietz, who has been diagnosed with AD dementia. He is from Stockholm, Sweden. He and his wife, Sophia, share their experiences from the earliest doubts and symptoms, through the diagnosis and adapting their lives to Daniel's condition. They also share their firm hopes for the future.
The neurologist following Daniel, Dr Silke Kern, talks about the importance of early testing for AD, and Dr Henrik Zetterberg, University of Gothenburg, and Geert Jannes, Scientific Director at Fujirebio, discuss the latest evolutions in AD testing and open doors to how the disease could be detected and monitored in the future.
The six-minute video can be watched, here: http://www.bbc.com/storyworks/natures-building-blocks/an-early-diagnosis